Published in J Clin Psychiatry on December 01, 2012
Non-pharmacological interventions for adults with mild cognitive impairment and early stage dementia: An updated scoping review. Mol Aspects Med (2015) 0.87
Non-pharmacological cognitive intervention for aging and dementia: Current perspectives. World J Clin Cases (2013) 0.80
Everyday Impact of Cognitive Interventions in Mild Cognitive Impairment: a Systematic Review and Meta-Analysis. Neuropsychol Rev (2016) 0.78
The efficacy of Cognitive training in patients with VAsCular Cognitive Impairment, No dEmentia (the Cog-VACCINE study): study protocol for a randomized controlled trial. Trials (2016) 0.75
The effects of holistic health group interventions on improving the cognitive ability of persons with mild cognitive impairment: a randomized controlled trial. Clin Interv Aging (2017) 0.75
Large recurrent microdeletions associated with schizophrenia. Nature (2008) 20.25
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nat Genet (2008) 10.52
Common variants conferring risk of schizophrenia. Nature (2009) 10.37
Mild cognitive impairment. Lancet (2006) 10.21
Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med (2012) 10.16
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol (2010) 8.74
Meta-analysis and imputation refines the association of 15q25 with smoking quantity. Nat Genet (2010) 8.55
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet (2013) 8.02
Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat Genet (2013) 7.44
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA (2009) 7.29
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol (2010) 6.55
Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. Nat Genet (2010) 6.49
CSF markers for incipient Alzheimer's disease. Lancet Neurol (2003) 6.12
A genome-wide investigation of SNPs and CNVs in schizophrenia. PLoS Genet (2009) 5.01
Classifying brain states and determining the discriminating activation patterns: Support Vector Machine on functional MRI data. Neuroimage (2005) 4.83
Disruption of the neurexin 1 gene is associated with schizophrenia. Hum Mol Genet (2008) 4.78
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov (2010) 4.55
Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat Genet (2009) 4.38
CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain (2006) 3.95
Multiple independent loci at chromosome 15q25.1 affect smoking quantity: a meta-analysis and comparison with lung cancer and COPD. PLoS Genet (2010) 3.91
Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement (2007) 3.75
Identification of common variants associated with human hippocampal and intracranial volumes. Nat Genet (2012) 3.73
Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol (2009) 3.65
Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol Aging (2003) 2.96
A comprehensive family-based replication study of schizophrenia genes. JAMA Psychiatry (2013) 2.93
Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol (2011) 2.84
Improved detection of common variants associated with schizophrenia and bipolar disorder using pleiotropy-informed conditional false discovery rate. PLoS Genet (2013) 2.68
Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS One (2010) 2.57
A primate-specific, brain isoform of KCNH2 affects cortical physiology, cognition, neuronal repolarization and risk of schizophrenia. Nat Med (2009) 2.37
Focal decline of cortical thickness in Alzheimer's disease identified by computational neuroanatomy. Cereb Cortex (2004) 2.36
Higher glucose levels associated with lower memory and reduced hippocampal microstructure. Neurology (2013) 2.33
Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. Neurobiol Aging (2010) 2.27
Neurexin 1 (NRXN1) deletions in schizophrenia. Schizophr Bull (2009) 2.25
Common variants at VRK2 and TCF4 conferring risk of schizophrenia. Hum Mol Genet (2011) 2.21
Automated cortical thickness measurements from MRI can accurately separate Alzheimer's patients from normal elderly controls. Neurobiol Aging (2006) 2.09
Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatry (2004) 2.07
Multivariate deformation-based analysis of brain atrophy to predict Alzheimer's disease in mild cognitive impairment. Neuroimage (2007) 2.03
Measurement of basal forebrain atrophy in Alzheimer's disease using MRI. Brain (2005) 2.03
Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients. Exp Neurol (2003) 1.99
Gene variants associated with schizophrenia in a Norwegian genome-wide study are replicated in a large European cohort. J Psychiatr Res (2010) 1.98
Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement (2013) 1.98
Improved detection of common variants associated with schizophrenia by leveraging pleiotropy with cardiovascular-disease risk factors. Am J Hum Genet (2013) 1.96
Maternally derived microduplications at 15q11-q13: implication of imprinted genes in psychotic illness. Am J Psychiatry (2011) 1.94
The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data. Brain Imaging Behav (2014) 1.90
Common variants on 8p12 and 1q24.2 confer risk of schizophrenia. Nat Genet (2011) 1.88
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement (2011) 1.87
Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol (2013) 1.84
Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. Arch Neurol (2005) 1.75
Genomewide association analysis followed by a replication study implicates a novel candidate gene for neuroticism. Arch Gen Psychiatry (2008) 1.75
Factor structure and external validity of the PANSS revisited. Schizophr Res (2005) 1.74
Grey matter correlates of clinical variables in amyotrophic lateral sclerosis (ALS): a neuroimaging study of ALS motor phenotype heterogeneity and cortical focality. J Neurol Neurosurg Psychiatry (2012) 1.70
Penetrance for copy number variants associated with schizophrenia. Hum Mol Genet (2010) 1.64
Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS One (2010) 1.62
White matter damage in Alzheimer disease and mild cognitive impairment: assessment with diffusion-tensor MR imaging and parallel imaging techniques. Radiology (2007) 1.61
Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. Alzheimers Dement (2011) 1.59
A pharmacological model for psychosis based on N-methyl-D-aspartate receptor hypofunction: molecular, cellular, functional and behavioral abnormalities. Biol Psychiatry (2006) 1.57
IFATS collection: The conditioned media of adipose stromal cells protect against hypoxia-ischemia-induced brain damage in neonatal rats. Stem Cells (2009) 1.57
Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer's disease. Neurobiol Aging (2011) 1.57
Automated detection of brain atrophy patterns based on MRI for the prediction of Alzheimer's disease. Neuroimage (2009) 1.55
Multivariate network analysis of fiber tract integrity in Alzheimer's disease. Neuroimage (2006) 1.52
Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. Trends Neurosci (2011) 1.51
The alternative splicing of tau exon 10 and its regulatory proteins CLK2 and TRA2-BETA1 changes in sporadic Alzheimer's disease. J Neurochem (2005) 1.51
Interplay between DISC1 and GABA signaling regulates neurogenesis in mice and risk for schizophrenia. Cell (2012) 1.48
The role of the major histocompatibility complex region in cognition and brain structure: a schizophrenia GWAS follow-up. Am J Psychiatry (2013) 1.48
Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Biomark Med (2012) 1.48